In the quest for health and wellness, Australians are constantly on the lookout for effective weight loss strategies. For ...

The European Medicines Agency (EMA) has advised that the drug can be used together with diet and physical activity to help ...

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

The makers of weight-loss drugs Wegovy and Zepbound are lowering prices significantly, effective immediately, to make them more affordable.

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...